Agenus (AGEN) to Release Quarterly Earnings on Tuesday

Agenus (NASDAQ:AGEN) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Agenus to post earnings of ($3.10) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. On average, analysts expect Agenus to post $-8 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $13.07 on Monday. Agenus has a 1-year low of $4.78 and a 1-year high of $42.60. The business has a 50-day moving average of $10.88 and a 200-day moving average of $13.32. The company has a market capitalization of $265.06 million, a price-to-earnings ratio of -0.92 and a beta of 1.25.

Insider Buying and Selling at Agenus

In other news, insider Garo H. Armen acquired 25,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were purchased at an average price of $13.00 per share, for a total transaction of $325,000.00. Following the completion of the purchase, the insider now directly owns 31,298 shares of the company’s stock, valued at approximately $406,874. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AGEN shares. StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $160.00 price target on shares of Agenus in a report on Thursday, March 14th. Finally, B. Riley reduced their price target on Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 18th.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.